Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01684163 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 369
- Enrollment target
NCT01684163: Completed Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT01684163 is a Phase 2 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 369 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01684163, a Phase 2 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 369 participants
- Enrollment target
Study Summary
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.
Interventions
- DRUG Placebo
- DRUG GLYX-13 5 mg/kg
- DRUG GLYX-13 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT01684163 record still lists
NCT01684163 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01684163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01684163 about?
NCT01684163 is a clinical study titled "Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants". GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another a...
What is the current status of trial NCT01684163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 369 participants. The study started on 2012-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01684163?
The interventions under investigation include: Placebo (DRUG), GLYX-13 5 mg/kg (DRUG), GLYX-13 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT01684163?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01684163's enrollment target sits among peer trials
369 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT06585410 · 369 participants · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia